CoChat

Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease

Open access
Huang, Yi-Long, Tsai, Tsung-Hsien, Shen, Zhao-Qing, Chan, Yun-Hsuan, Tu, Chih-Wei, Tung, Chien-Yi, Wang, Pei-Ning, Tsai, Ting-Fen · 2025 · Alzheimer's Research & Therapy

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Effective treatment for Alzheimer's disease (AD) remains an unmet need. Thus, identifying patients with mild cognitive impairment (MCI) who are at high-risk of progressing to AD is crucial for early intervention. METHODS: Blood-based transcriptomics analyses were performed using a longitudinal study cohort to compare progressive MCI (P-MCI, n = 28), stable MCI (S-MCI, n = 39), and AD patients (n = 49). Statistical DESeq2 analysis and machine learning methods were employed to identify differentially expressed genes (DEGs) and develop prediction models. RESULTS: We discovered a remarkable gender-specific difference in DEGs that distinguish P-MCI from S-MCI. Machine learning models achieved high accuracy in distinguishing P-MCI from S-MCI (AUC 0.93), AD from S-MCI (AUC 0.94), and AD from P-MCI (AUC 0.92). An 8-gene signature was identified for distinguishing P-MCI from S-MCI. CONCLUSIONS: Blood-based transcriptomic biomarker signatures show great utility in identifying high-risk MCI patients, with mitochondrial processes emerging as a crucial contributor to AD progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-024-01651-0

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Integrated study by statistical analysis using DESeq2 and machine learning methods to discover biomarker signatures that allow identification of MCI patients at high risk of AD. A During the 10-year longitudinal study, patients with MCI were classified as stable MCI (S-MCI, ≥ 4y) or progressive MCI (P-MCI, < 3y progressing to AD). Independently, 36 patients with AD were also selected. All subjects underwent whole transcriptome profiling of white blood cells via RNA-seq. B Schematic flow chart for identification of key genes derived from the RNA-seq data. Differential gene expression analysis was conducted by DESeq2 using the expected counts as inputs. For machine learning, count data are transformed into TPM values for feature selection and model construction. C, D Volcano plots showing significant upregulated and downregulated genes of P-MCI versus S-MCI based on DESeq2 analyses of males (C) or females (D). E Heatmap for 501 genes (204 upregulated and 297 downregulated) that differentially modulated in male P-MCI group. F Heatmap for 879 genes (440 upregulated and 439 downregulated) that differentially modulated in female P-MCI group. G A Venn diagram comparing significantly regulated genes found in male and female patients defined as P-MCI compared with S-MCI patients. H A Venn diagram comparing significantly dysregulated pathways found in male and female P-MCI patients compared with S-MCI patients. MCI, mild cognitive impairment; DEG, differentially expressed gene; IPA, ingenuity pathway analysis
Fig. 1 Integrated study by statistical analysis using DESeq2 and machine learning methods to discover biomarker signatures that allow identification of MCI patients at high risk of AD. A During the 10-year longitudinal study, patients with MCI were classified as stable MCI (S-MCI, ≥ 4y) or progressive MCI (P-MCI, < 3y progressing to AD). Independently, 36 patients with AD were also selected. All subjects underwent whole transcriptome profiling of white blood cells via RNA-seq. B Schematic flow chart for identification of key genes derived from the RNA-seq data. Differential gene expression analysis was conducted by DESeq2 using the expected counts as inputs. For machine learning, count data are transformed into TPM values for feature selection and model construction. C, D Volcano plots showing significant upregulated and downregulated genes of P-MCI versus S-MCI based on DESeq2 analyses of males (C) or females (D). E Heatmap for 501 genes (204 upregulated and 297 downregulated) that differentially modulated in male P-MCI group. F Heatmap for 879 genes (440 upregulated and 439 downregulated) that differentially modulated in female P-MCI group. G A Venn diagram comparing significantly regulated genes found in male and female patients defined as P-MCI compared with S-MCI patients. H A Venn diagram comparing significantly dysregulated pathways found in male and female P-MCI patients compared with S-MCI patients. MCI, mild cognitive impairment; DEG, differentially expressed gene; IPA, ingenuity pathway analysisCC BY-NC-ND · PubMed Central
Fig. 2 Gender-specific differences in the biological pathways enriched in P-MCI patients compared to S-MCI patients. A Bubble plot depicting the significant canonical pathways based on male P-MCI vs. S-MCI DEGs. B GSEA shows enrichment of Alzheimer’s disease and B cell receptor signaling pathways in the male P-MCI vs. S-MCI. C Bubble plot depicting the significant canonical pathways based on female P-MCI vs. S-MCI DEGs. D GSEA shows enrichment of chemokine signaling pathway, natural killer cell-mediated cytotoxicity, and neurotrophin signaling pathway in the female P-MCI vs. S-MCI. E A schematic diagram of B cell survival signaling and GnRH Signaling pathways based on male P-MCI vs. S-MCI DEGs. F A schematic diagram of LPS-TLR4, Insulin-PI3K-AKT-FOXO, and IL-6-HIF1α pathways based on female P-MCI vs. S-MCI DEGs. All up-regulated DEGs are colored in red, while down-regulated are colored in blue. Black squares represent non-significant changes and grey squares demonstrate undetected gene expression. *, p < 0.05 in the DESeq2 analysis result with age as a covariate. GSEA, gene set enrichment analysis; NES, normalized enrichment score; ERAD, Endoplasmic Reticulum-Associated Degradation. MCI, mild cognitive impairment; P-MCI, Progressive MCI; S-MCI, Stable MCI
Fig. 2 Gender-specific differences in the biological pathways enriched in P-MCI patients compared to S-MCI patients. A Bubble plot depicting the significant canonical pathways based on male P-MCI vs. S-MCI DEGs. B GSEA shows enrichment of Alzheimer’s disease and B cell receptor signaling pathways in the male P-MCI vs. S-MCI. C Bubble plot depicting the significant canonical pathways based on female P-MCI vs. S-MCI DEGs. D GSEA shows enrichment of chemokine signaling pathway, natural killer cell-mediated cytotoxicity, and neurotrophin signaling pathway in the female P-MCI vs. S-MCI. E A schematic diagram of B cell survival signaling and GnRH Signaling pathways based on male P-MCI vs. S-MCI DEGs. F A schematic diagram of LPS-TLR4, Insulin-PI3K-AKT-FOXO, and IL-6-HIF1α pathways based on female P-MCI vs. S-MCI DEGs. All up-regulated DEGs are colored in red, while down-regulated are colored in blue. Black squares represent non-significant changes and grey squares demonstrate undetected gene expression. *, p < 0.05 in the DESeq2 analysis result with age as a covariate. GSEA, gene set enrichment analysis; NES, normalized enrichment score; ERAD, Endoplasmic Reticulum-Associated Degradation. MCI, mild cognitive impairment; P-MCI, Progressive MCI; S-MCI, Stable MCICC BY-NC-ND · PubMed Central
Fig. 3 Machine learning models to differentiate MCI and AD, and identify high-risk P-MCI patients. A The top differentiating features ranked by selection frequency are shown for three different classification models: (i) P-MCI vs. S-MCI; (ii) AD vs. S-MCI; (iii) AD vs. P-MCI. B PCA score plot of all 174 features from joint selected genes of all three classifications. C ROC curves of three groups of classifiers: (i) P-MCI vs. S-MCI; (ii) AD vs. P-MCI; (iii) AD vs. S-MCI using optimal number of selected features by five-fold cross validation. The 95% confidence interval (CI) values are also indicated. D Performance assessment of all three classifiers: (i) P-MCI vs. S-MCI; (ii) AD vs. S-MCI; (iii) AD vs. P-MCI using the top selected features. For each classifier, results are shown for all subjects combined (♀ + ♂), for females only (♀), and for males only (♂). The results are presented as means. MCI, mild cognitive impairment; P-MCI, Progressive MCI; S-MCI, Stable MCI
Fig. 3 Machine learning models to differentiate MCI and AD, and identify high-risk P-MCI patients. A The top differentiating features ranked by selection frequency are shown for three different classification models: (i) P-MCI vs. S-MCI; (ii) AD vs. S-MCI; (iii) AD vs. P-MCI. B PCA score plot of all 174 features from joint selected genes of all three classifications. C ROC curves of three groups of classifiers: (i) P-MCI vs. S-MCI; (ii) AD vs. P-MCI; (iii) AD vs. S-MCI using optimal number of selected features by five-fold cross validation. The 95% confidence interval (CI) values are also indicated. D Performance assessment of all three classifiers: (i) P-MCI vs. S-MCI; (ii) AD vs. S-MCI; (iii) AD vs. P-MCI using the top selected features. For each classifier, results are shown for all subjects combined (♀ + ♂), for females only (♀), and for males only (♂). The results are presented as means. MCI, mild cognitive impairment; P-MCI, Progressive MCI; S-MCI, Stable MCICC BY-NC-ND · PubMed Central
Fig. 4 Enriched pathways based on the top features selected by machine learning that are then used to discriminate between P-MCI, S-MCI, and AD. A, C, E Bubble plots representing functional enrichment of important/key mRNAs selected by P-MCI vs. S-MCI, AD vs. P-MCI, and AD vs. S-MCI models. B A representation of ABCB1, TSP1, and mitochondrial function-related mRNAs selected by machine learning during the P-MCI vs. S-MCI classifier. D A representation of mRNAs associated with chromatin remodeling and DNA repair, mitochondrial process, proteostasis, and transporters, identified by machine learning during the AD vs. P-MCI classifier. Figure created with BioRender.com
Fig. 4 Enriched pathways based on the top features selected by machine learning that are then used to discriminate between P-MCI, S-MCI, and AD. A, C, E Bubble plots representing functional enrichment of important/key mRNAs selected by P-MCI vs. S-MCI, AD vs. P-MCI, and AD vs. S-MCI models. B A representation of ABCB1, TSP1, and mitochondrial function-related mRNAs selected by machine learning during the P-MCI vs. S-MCI classifier. D A representation of mRNAs associated with chromatin remodeling and DNA repair, mitochondrial process, proteostasis, and transporters, identified by machine learning during the AD vs. P-MCI classifier. Figure created with BioRender.comCC BY-NC-ND · PubMed Central
Fig. 5 Multifaceted biological processes and pathways that are identified to be associated with AD progression. Our study revealed that multiple biological pathways and processes appear to be involved in the rapid progression of high-risk patients from P-MCI to AD, and that an integrated investigation of DESeq2 and machine learning methods should accelerate the discovery of biomarker signatures that will reveal the multifaceted nature of the molecular pathogenesis during AD disease progression
Fig. 5 Multifaceted biological processes and pathways that are identified to be associated with AD progression. Our study revealed that multiple biological pathways and processes appear to be involved in the rapid progression of high-risk patients from P-MCI to AD, and that an integrated investigation of DESeq2 and machine learning methods should accelerate the discovery of biomarker signatures that will reveal the multifaceted nature of the molecular pathogenesis during AD disease progressionCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 16

Metadata

Authors
Huang, Y.-L., Tsai, T.-H., Shen, Z.-Q., Chan, Y.-H., Tu, C.-W., Tung, C.-Y., Wang, P.-N., & Tsai, T.-F.
Affiliations
  • National Yang Ming Chiao Tung University (TW)
  • Acer (Taiwan) (TW)
Corresponding author
  • Tsai, Tsung-Hsien
  • Wang, Pei-Ning
  • Tsai, Ting-Fen
Venue
Alzheimer's Research & Therapy
Published
2025-01-03
Volume
17
Issue
1
Pages
3-3
ISSN
1758-9193 (ISSN-L)
OpenAlex
W4406039902
Cited by
13
References
38
Citations by year
2026: 6 · 2025: 7
FWCI
8.70
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • NHRI Institutional Repository (submittedVersion)
Funders
  • Shanghai Educational Development Foundation
  • Ministry of Education, India
  • National Health Research Institutes
  • National Science and Technology Council (MOST 110-2320-B-A49A-529-MY3)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, mild cognitive impairment, disease progression prediction, blood transcriptomics, gene expression biomarkers, differentially expressed genes, early intervention
MeSH terms
Machine Learning, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Longitudinal Studies, Male, Biomarkers, Disease Progression, Transcriptome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease. https://app.cochat.ai/papers/10.1186/s13195-024-01651-0
The paper
Huang, Y.-L., Tsai, T.-H., Shen, Z.-Q., Chan, Y.-H., Tu, C.-W., Tung, C.-Y., Wang, P.-N., & Tsai, T.-F. (2025). Transcriptomic predictors of rapid progression from mild cognitive impairment to Alzheimer's disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-024-01651-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.